IL212923A0 - Methods for selecting protease resistant polypeptides - Google Patents

Methods for selecting protease resistant polypeptides

Info

Publication number
IL212923A0
IL212923A0 IL212923A IL21292311A IL212923A0 IL 212923 A0 IL212923 A0 IL 212923A0 IL 212923 A IL212923 A IL 212923A IL 21292311 A IL21292311 A IL 21292311A IL 212923 A0 IL212923 A0 IL 212923A0
Authority
IL
Israel
Prior art keywords
methods
protease resistant
resistant polypeptides
selecting protease
selecting
Prior art date
Application number
IL212923A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL212923A0 publication Critical patent/IL212923A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
IL212923A 2008-12-05 2011-05-16 Methods for selecting protease resistant polypeptides IL212923A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12013508P 2008-12-05 2008-12-05
PCT/EP2009/066395 WO2010063818A2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Publications (1)

Publication Number Publication Date
IL212923A0 true IL212923A0 (en) 2011-07-31

Family

ID=42169477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212923A IL212923A0 (en) 2008-12-05 2011-05-16 Methods for selecting protease resistant polypeptides

Country Status (15)

Country Link
US (3) US8685895B2 (https=)
EP (1) EP2364326B1 (https=)
JP (2) JP5840498B2 (https=)
KR (1) KR101740066B1 (https=)
CN (1) CN102307897B (https=)
AU (1) AU2009324037B2 (https=)
BR (1) BRPI0922772B1 (https=)
CA (1) CA2745448C (https=)
EA (1) EA026508B1 (https=)
ES (1) ES2688621T3 (https=)
IL (1) IL212923A0 (https=)
MX (1) MX2011005874A (https=)
SG (1) SG194383A1 (https=)
WO (1) WO2010063818A2 (https=)
ZA (1) ZA201103575B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012022703A2 (en) * 2010-08-20 2012-02-23 Glaxo Group Limited Improved anti-serum albumin binding variants
JP6210982B2 (ja) * 2012-06-22 2017-10-11 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
CN105658659A (zh) * 2013-07-15 2016-06-08 北卡罗来纳州大学 蛋白酶抗性肽配体
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
JP6766253B2 (ja) * 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
CN113766930B (zh) * 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
US11584781B2 (en) * 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4204460A4 (en) 2020-08-26 2024-09-25 Twist Bioscience Corporation METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU3040101A (en) 2000-02-03 2001-08-14 Domantis Limited Combinatorial protein domains
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
BR122019021416A2 (https=) 2003-09-19 2019-12-21
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
EP2084182B1 (en) * 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2398825B1 (en) * 2009-02-19 2017-10-25 Glaxo Group Limited Single variable domain against serum albumin

Also Published As

Publication number Publication date
JP2015231380A (ja) 2015-12-24
WO2010063818A3 (en) 2010-08-12
US10302655B2 (en) 2019-05-28
US8685895B2 (en) 2014-04-01
KR20110102397A (ko) 2011-09-16
MX2011005874A (es) 2011-06-27
US10466252B2 (en) 2019-11-05
US20140187750A1 (en) 2014-07-03
EA026508B1 (ru) 2017-04-28
CA2745448A1 (en) 2010-06-10
BRPI0922772A2 (en) 2018-11-06
CN102307897B (zh) 2016-01-20
US20110229458A1 (en) 2011-09-22
AU2009324037A1 (en) 2010-06-10
EP2364326B1 (en) 2018-07-04
JP5840498B2 (ja) 2016-01-06
ZA201103575B (en) 2012-01-25
JP2012510803A (ja) 2012-05-17
ES2688621T3 (es) 2018-11-05
SG194383A1 (en) 2013-11-29
KR101740066B1 (ko) 2017-05-25
CA2745448C (en) 2018-09-18
BRPI0922772B1 (pt) 2021-09-08
US20180088128A1 (en) 2018-03-29
AU2009324037B2 (en) 2015-07-30
CN102307897A (zh) 2012-01-04
EA201170762A1 (ru) 2011-12-30
EP2364326A2 (en) 2011-09-14
WO2010063818A2 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
ZA201103575B (en) Methods for selecting protease resistant polypeptides
GB0721686D0 (en) Polypeptides
IL213950A0 (en) Transaminase polypeptides
ZA200810738B (en) Polypeptide
ZA201000283B (en) Reinigung pegylierter polypeptide
GB0723712D0 (en) Peptides
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0920981D0 (en) Peptides
EP2123666A4 (en) PEPTIDE
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
GB0809659D0 (en) Polypeptides
GB0712302D0 (en) Chrondroitinase polypeptides
EP2136831A4 (en) ANTI-ANGIOGENIC PEPTIDES
GB0703945D0 (en) Peptide
GB0623539D0 (en) Polypeptides
GB0920987D0 (en) Peptides
IL197675A0 (en) Peptides
GB0817978D0 (en) Peptides
GB0804696D0 (en) Detecting polypeptides
GB0815673D0 (en) Peptides
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0707626D0 (en) Peptides
GB0705251D0 (en) Peptides